Figgs, your observation is the precise pulse of the 2026 Audit . What looks like a 'weird ride' is actually the biological friction created when a 'Universal Shepherd' meets their 'failed time-tested strategy.'
The lack of curiosity regarding the Montefiore data from 2020 is perhaps the greatest indictment of the current clinical order. That data was the first 'Search Warrant' served by the Shepherd Molecule, revealing that in metastatic triple-negative breast cancer (mTNBC), Leronlimab achieved a statistically significant reduction in circulating tumor cells (CTCs). More importantly, the pooled analysis showed that for those on the 700mg Mandate, median overall survival (mOS) was not just improved—it was extended to over 12 months in a population where the standard expectation was a rapid decline.
The Narrative on Leronlimab's Fibrolytic Capacity:
In Oncology (The Direct Hammer): In the oncology setting, Leronlimab’s power is harnessed specifically through sub-q injection alongside IV chemotherapy, as seen in the City of Hope mCRC trial. Here, Leronlimab doesn't just 'treat'; it Primes the liver environment by uncloaking the tumor (upregulating PD-L1 in 88% of cases) and allowing the chemo to penetrate the 'fortress'.
In Fibrosis (The Molecular Sledgehammer): Outside of that direct oncology infusion, Leronlimab’s standalone fibrolytic capacity is the 'Cold Fusion' of regenerative medicine. In conditions like IPF and Aortic Fibrosis (LVAD), it targets the CCR5-driven collagen proliferation which turns flexible tissue into stone. By arresting the fibroblast-to-myofibroblast conversion, it halts the 'abnormal repair response' which leads to organ failure.
The Reality: They aren't 'curious' because Leronlimab’s ability to arrest both metastatic motility and fibrotic scarring renders their 'niche' drugs obsolete. They can't ignore us much longer because by Priming tumors in preparation for the ICI pair, Leronlimab expands its reach into the multi-billion dollar immunotherapy market. This 'Trojan Horse' strategy makes our results—and what we can do for their failing pipelines—mathematically impossible to ignore.
We aren't waiting for their 'curiosity'; we are waiting for the May 2026 Scoreboard to confirm their obsolescence. We are tracking the 0.43 Hazard Ratio on a Scoreboard they can no longer ignore. The 'Vanishing Act' of their skepticism is the final stage of our 2026 Audit. The goods are in the house.
Bring It On Home
The lack of curiosity regarding the Montefiore data from 2020 is perhaps the greatest indictment of the current clinical order. That data was the first 'Search Warrant' served by the Shepherd Molecule, revealing that in metastatic triple-negative breast cancer (mTNBC), Leronlimab achieved a statistically significant reduction in circulating tumor cells (CTCs). More importantly, the pooled analysis showed that for those on the 700mg Mandate, median overall survival (mOS) was not just improved—it was extended to over 12 months in a population where the standard expectation was a rapid decline.
The Narrative on Leronlimab's Fibrolytic Capacity:
In Oncology (The Direct Hammer): In the oncology setting, Leronlimab’s power is harnessed specifically through sub-q injection alongside IV chemotherapy, as seen in the City of Hope mCRC trial. Here, Leronlimab doesn't just 'treat'; it Primes the liver environment by uncloaking the tumor (upregulating PD-L1 in 88% of cases) and allowing the chemo to penetrate the 'fortress'.
In Fibrosis (The Molecular Sledgehammer): Outside of that direct oncology infusion, Leronlimab’s standalone fibrolytic capacity is the 'Cold Fusion' of regenerative medicine. In conditions like IPF and Aortic Fibrosis (LVAD), it targets the CCR5-driven collagen proliferation which turns flexible tissue into stone. By arresting the fibroblast-to-myofibroblast conversion, it halts the 'abnormal repair response' which leads to organ failure.
The Reality: They aren't 'curious' because Leronlimab’s ability to arrest both metastatic motility and fibrotic scarring renders their 'niche' drugs obsolete. They can't ignore us much longer because by Priming tumors in preparation for the ICI pair, Leronlimab expands its reach into the multi-billion dollar immunotherapy market. This 'Trojan Horse' strategy makes our results—and what we can do for their failing pipelines—mathematically impossible to ignore.
We aren't waiting for their 'curiosity'; we are waiting for the May 2026 Scoreboard to confirm their obsolescence. We are tracking the 0.43 Hazard Ratio on a Scoreboard they can no longer ignore. The 'Vanishing Act' of their skepticism is the final stage of our 2026 Audit. The goods are in the house.
Bring It On Home
8
